1. Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

5. Continuous Lenalidomide in Nontransplanted MM, The FIRST Trial

6. Bor/Len/Dex vs Len/Dex: SWOG S0777 Data 3-Drug Regimen as Initial Induction

7. Maintenance Therapy: The Nurse’s Role

8. Multiple Myeloma Plasma Cell Malignancy

9. Diagnostic Criteria MM Requiring Therapy

10. Maintenance Lenalidomide Key Trials

11. Meta-Analysis Results of Maintenance Lenalidomide

12. Risk Stratification

13. Bortezomib in the Maintenance Setting

14. HOVON-65/GMMG-HD4: Bortezomib Induction and Maintenance by Cytogenetic Risk

15. IFM 2009 Study ASCT vs No ASCT

16. Ixazomib vs Placebo Following ASCT in Newly Diagnosed MM, Phase 3 Tourmaline-MM3 Trial

17. Cytogenetic Risk Features

18. RVD Maintenance Therapy After ASCT

19. Communicating With Patients

20. Be Prepared for Complex Questions

21. Tools for Optimizing Adherence

22. Monitoring Patients After Initial Therapy Asymptomatic, Nonprogressing

23. Toxicities and Maintenance Therapy

24. Select Adverse Events and Prophylaxis by Drug Class

25. Bone-Modifying Agents

26. Key Takeaways for Nurses

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)

30. Abbreviations (cont)

31. Abbreviations (cont)